As multiplexing platforms become more scalable and flexible, biomarkers are playing an increasingly central role in both preclinical and clinical decision-making.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.